By Gaetan Burgio CRISPR/Cas9 genome editing has dramatically changed our way to perform biological experiments. While highly efficient and easy to use, one limitation with CRISPR/Cas9 mediated genome editing technology is the occurrence of off-target effects and the restriction of the PAM recognition sequence. Many modifications from the original system have been proposed to improve its efficiency, specificity and to avoid off-target effects. Recently a new system based on the bacteria Natronobacterium gregory Argonaute (NgAgo) was proposed as a serious alternative to CRISPR/Cas9. NgAgo …Read More
Has it really been 10 years since induced pluripotent stem cells (aka IPS cells or IPSC) came onto the scene in the stem cell field? Yes, it was a decade ago that now Nobel Laureate Shinya Yamanaka (山中伸弥) published that seminal Cell paper on reprogramming to make mouse IPS cells and then human IPS cells came the next year. From the moment I read that first mouse IPS cell paper, I was very excited about the science and the ideas in it. The domain …Read More
Will NgAgo strongly challenge CRISPR in coming years? Take our poll and also see the results to find out what others thought. 2020 update: NgoAgo has ending up going nowhere, but 4 years ago we didn’t know that would be it’s fate although some of us were skeptical early on.
CIRM announced recently the funding of a number of exciting new studies. ViaCyte received additional funding to support its development of its hESC-based pancreatic progenitor cell product PEC-Direct clinic trials. This work is very promising. CIRM also funded additional diabetes-related research by Humacyte on engineering blood vessels for use in dialysis, which is very creative. I was happy to see that my colleague here at UC Davis School of Medicine, Professor David Segal, received funding for a cutting edge grant on using gene editing for …Read More